Journal
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
Volume 14, Issue 8, Pages 945-958Publisher
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2016.0101
Keywords
-
Categories
Funding
- Eisai Inc.
- Genentech, Inc.
- Seattle Genetics
- Acerta
- Amgen Inc.
- AstraZeneca Pharmaceuticals LP
- Bristol-Myers Squibb Company
- Corvus
- GlaxoSmithKline
- MedImmune Inc.
- Merck Co, Inc.
- Novartis Pharmaceuticals Corporation
- Merck Co., Inc.
- Roche Laboratories, Inc.
- X4 Pharmaceuticals
- AstraZeneca Pharmaceuticals/MedImmune
- Celldex Therapeutics
Ask authors/readers for more resources
The NCCN Guidelines for Melanoma have been significantly revised over the past few years in response to emerging data on a number of novel agents and treatment regimens. These NCCN Guidelines Insights summarize the data and rationale supporting extensive changes to the recommendations for systemic therapy in patients with metastatic or unresectable melanoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
